COMPANIES A small cannon sits on the window sill in David Brennan’s London office, as if ready to defend him from any angry investors seeking better returns from AstraZeneca, the Anglo-Swedish pharmaceutical group that he runs.
Yet, in recent weeks, the unusually favourable market conditions for his company have meant that he has had no need to contemplate loading the weapon, a gift from bankers involved in AZ’s takeover of CAT, the UK biotech group, in 2006.
